Turner Jessica, Begum Tahmina, Smalligan Roger D
Texas Tech University Health Sciences Center, Amarillo, TX, USA.
J Investig Med High Impact Case Rep. 2016 Aug 29;4(3):2324709616663231. doi: 10.1177/2324709616663231. eCollection 2016 Jul-Sep.
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are relatively new antihyperglycemic agents that lower renal glucose reabsorption. They are used as adjunctive therapy to standard diabetes treatment.
We present the case of a 62-year-old woman with a past medical history of type 2 diabetes mellitus and sudden-onset diabetic ketoacidosis (DKA). Use of canagliflozin, a SGLT-2 inhibitor, was determined to be the cause of the DKA. The patient ultimately recovered after 5 days in the intensive care unit. She was changed to long- and short-acting insulins and instructed to avoid canagliflozin.
Although SGLT-2 inhibitors are effective at lowering a patient's hemoglobin A1C, physicians must be aware of the rare but dangerous potential adverse effect of inducing DKA. This article reports an illustrative case and presents a review of the literature.
钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂是一类相对较新的降糖药物，可降低肾脏对葡萄糖的重吸收。它们被用作标准糖尿病治疗的辅助疗法。
我们报告一例62岁女性患者，既往有2型糖尿病病史，突发糖尿病酮症酸中毒（DKA）。经判定，使用SGLT-2抑制剂卡格列净是导致DKA的原因。该患者在重症监护病房治疗5天后最终康复。她改用了长效和短效胰岛素，并被嘱咐避免使用卡格列净。
尽管SGLT-2抑制剂在降低患者糖化血红蛋白方面有效，但医生必须意识到诱发DKA这种罕见但危险的潜在不良反应。本文报告了一个典型病例并对相关文献进行了综述。
